Metformin Vitabalans (Metformin Hydrochloride)

Metformin acts primarily by inhibiting mitochondrial complex I, which reduces hepatic gluconeogenesis. The drug also enhances peripheral glucose uptake in muscle and fat tissue and modestly decreases intestinal glucose absorption, collectively leading to lower blood‑glucose levels without stimulating insulin secretion.

The dose of Metformin Vitabalans is individualized by the prescribing clinician based on factors such as the patient’s renal function, glycaemic targets, tolerability, and concomitant medications. No fixed regimen is provided here; the prescriber will decide the appropriate strength and frequency.

Safety data for Metformin in pregnancy are limited, and the drug is classified as pregnancy category unknown. It may be used when the potential benefit justifies the potential risk. Metformin is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Metformin Vitabalans product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metformin belongs to the biguanide class and differs from sulfonylureas, which stimulate insulin release, and from insulin itself, which replaces hormone. Metformin improves insulin sensitivity without causing hypoglycaemia when used alone, making it a first‑line therapy in most guidelines for type 2 diabetes.

Metformin Vitabalans should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the package is tightly closed throughout its shelf life.

Metformin Vitabalans is taken orally, usually with a glass of water. It can be taken with meals to reduce gastrointestinal discomfort. The exact timing and frequency are determined by the prescribing clinician based on the individual treatment plan.

The most serious adverse reactions include lactic acidosis, which is rare but potentially fatal, severe skin reactions such as Stevens‑Johnson syndrome, and rare cases of hepatic failure. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, abdominal discomfort, or skin blistering.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in those with severe hepatic disease. Caution is also advised in patients with conditions that predispose to hypoxia or dehydration.